UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 79.818
NA - Nord America 3.516
AS - Asia 1.479
SA - Sud America 171
Continente sconosciuto - Info sul continente non disponibili 162
AF - Africa 29
OC - Oceania 3
Totale 85.178
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 78.973
US - Stati Uniti d'America 3.467
SG - Singapore 579
CN - Cina 544
UA - Ucraina 257
SE - Svezia 193
BR - Brasile 133
VN - Vietnam 132
FI - Finlandia 93
DE - Germania 86
GB - Regno Unito 74
FR - Francia 62
HK - Hong Kong 55
IN - India 41
KR - Corea 32
BD - Bangladesh 23
CA - Canada 22
RU - Federazione Russa 19
PL - Polonia 12
AR - Argentina 11
IQ - Iraq 11
MX - Messico 11
NL - Olanda 11
ZA - Sudafrica 11
BE - Belgio 9
JP - Giappone 9
TR - Turchia 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
CO - Colombia 6
EU - Europa 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
JM - Giamaica 5
CL - Cile 4
ID - Indonesia 4
IE - Irlanda 4
KE - Kenya 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
SV - El Salvador 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
CR - Costa Rica 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
KZ - Kazakistan 2
MN - Mongolia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ES - Italia 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
KW - Kuwait 1
LU - Lussemburgo 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 85.022
Salva come PNG Salva come JPEG
Città #
Cagliari 77.732
Uta 1.071
Singapore 316
Ashburn 304
Woodbridge 294
Fairfield 288
Chandler 264
San Jose 206
Ann Arbor 143
Jacksonville 140
Nyköping 136
Houston 132
Seattle 125
Boardman 117
Wilmington 117
Dallas 107
Dearborn 102
Beijing 98
Cambridge 97
Los Angeles 81
New York 77
Council Bluffs 58
Helsinki 54
Santa Clara 54
Hong Kong 43
Nanjing 40
Shanghai 37
Ho Chi Minh City 35
Lauterbourg 35
Hefei 32
Boston 31
Seoul 29
Guangzhou 26
Hanoi 25
Milan 24
Buffalo 22
Shenyang 20
The Dalles 20
Redwood City 19
San Diego 18
Dong Ket 16
Jinan 15
Hebei 13
Orem 13
Norwalk 12
Changsha 11
Jiaxing 11
Phoenix 11
Rome 11
Toronto 11
Chicago 10
Mountain View 10
Munich 10
Brooklyn 9
Brussels 9
Frankfurt am Main 9
Nanchang 9
Redondo Beach 9
Hangzhou 8
London 8
Orange 8
Dhaka 7
Düsseldorf 7
São Paulo 7
Tianjin 7
Verona 7
Haiphong 6
Montreal 6
Ningbo 6
Oristano 6
Padova 6
Tashkent 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Amsterdam 5
Atlanta 5
Belo Horizonte 5
Columbus 5
Mexico City 5
Modrice 5
Pune 5
Rio de Janeiro 5
Tokyo 5
Washington 5
Baghdad 4
Campinas 4
Chengdu 4
Chennai 4
Da Nang 4
Gurgaon 4
Indore 4
Kathmandu 4
Kingston 4
Kunming 4
La Paz 4
Manchester 4
Nuremberg 4
Paris 4
Portsmouth 4
Totale 82.991
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.486
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.263
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.183
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.136
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.024
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.950
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.856
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.792
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.737
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.709
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.693
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.679
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.642
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.552
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.503
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.429
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.243
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.238
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.177
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.133
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.102
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.101
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.977
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.955
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.892
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.882
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.755
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.709
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.662
null 1.651
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.641
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.424
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.295
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.293
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.177
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.104
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 1.010
null 981
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 971
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 560
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 336
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 275
Totale 85.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.326
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.418 0 284 320 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20256.979 1.324 1.426 1.166 910 527 563 607 71 116 77 102 90
2025/20262.939 219 117 258 173 251 225 764 144 171 349 152 116
2026/2027177 92 85 0 0 0 0 0 0 0 0 0 0
Totale 85.178